Welcome to our dedicated page for Xtl Biopharmaceu SEC filings (Ticker: XTLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot trial milestones or cash-runway clues in XTL Biopharmaceuticals’ dense disclosures? As a clinical-stage biotech, XTL’s SEC documents bury critical details—immunology study results, licensing revenue, and dilution risks—in hundreds of technical pages. Investors hunting for “XTL Biopharmaceuticals insider trading Form 4 transactions” or the latest “XTL Biopharmaceuticals quarterly earnings report 10-Q filing” know the challenge.
Stock Titan turns that challenge into clarity. Our AI reads every 10-K, 10-Q, 8-K, S-1, and DEF 14A the moment it hits EDGAR, then serves up plain-English briefs. Want a quick take on R&D spend trends or a cash-flow bridge? You’ll find it under “XTL Biopharmaceuticals SEC filings explained simply.” Need real-time alerts for “XTL Biopharmaceuticals Form 4 insider transactions real-time” or to compare option grants in the “XTL Biopharmaceuticals proxy statement executive compensation”? One dashboard delivers it all, including push notifications on significant 8-K events such as trial suspensions—“XTL Biopharmaceuticals 8-K material events explained” without the legalese.
Dig deeper into what matters for this pipeline-focused company. Our summaries highlight hCDR1 efficacy readouts, rHuEPO survival data, and any going-concern language—key insights you’ll notice instantly in the “XTL Biopharmaceuticals annual report 10-K simplified.” Use AI-generated tables to track dilution from secondary offerings, monitor “XTL Biopharmaceuticals executive stock transactions Form 4,” and compare each “XTL Biopharmaceuticals earnings report filing analysis” across quarters. From pre-market strategy sessions to end-of-day risk checks, professional investors rely on Stock Titan’s comprehensive, real-time coverage to save hours and make informed decisions faster.
XTL Biopharmaceuticals Ltd. announced a board change. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors due to personal reasons. The company stated his resignation was not the result of any disagreement with the company or its management. Noam Band, the Company’s Chief Executive Officer, was appointed to the Board of Directors in his place, effective immediately.
XTL is an IP portfolio company that owns 100% of The Social Proxy Ltd., a web data company, and has sublicensed an IP portfolio around hCDR1 for treating lupus (SLE). The company trades on Nasdaq (XTLB) and the TASE (XTLB.TA).
FAQ
What is the current stock price of Xtl Biopharmaceu (XTLB)?
What is the market cap of Xtl Biopharmaceu (XTLB)?
